;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AVI-7100: Phase I data

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Product: AVI-7100 Business: Infectious Molecular target: NA Description: RNA-based influenza therapeutic based on phosphorodiamidate morpholino oligomer (PMO) …

    Published on 11/10/2014
  • Dabrafenib: Additional Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Dabrafenib (Tafinlar) (GSK2118436) Business: Cancer Molecular target: BRAF Description: Oral BRAF protein kinase inhibitor Indication: Treat advanced or …

    Published on 11/10/2014
  • Enclomiphene: Additional Phase III data

    Repros Therapeutics Inc. (NASDAQ:RPRX), The Woodlands, Texas Product: Enclomiphene (Androxal) Business: Endocrine/Metabolic Molecular target: Androgen receptor; Estrogen receptor Description: Trans-isomer of clomiphene …

    Published on 11/10/2014
  • EPZ-5676: Additional Phase I data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Product: EPZ-5676 Business: Cancer Molecular target: Histone methyltransferase DOT1L (DOT1L) Description: Histone methyltransferase …

    Published on 11/10/2014
  • Intranasal sumatriptan powder: Additional Phase III data

    Avanir Pharmaceuticals Inc. (NASDAQ:AVNR), Aliso Viejo, Calif. OptiNose Inc., Yardley, Pa. Product: Intranasal sumatriptan powder, OptiNose sumatriptan (AVP-825) Business: Neurology Molecular target: NA Description: Low…

    Published on 11/10/2014
  • IV CR845: Clinical trial data

    Cara Therapeutics Inc. (NASDAQ:CARA), Shelton, Conn. Chong Kun Dang Pharmaceutical Corp. (KSE:001630), Seoul, South Korea Maruishi Pharmaceutical Co. Ltd., Osaka, Japan Product: IV CR845 Business: Neurology Molecular …

    Published on 11/10/2014
  • LentiGlobin BB305 gene therapy: Additional Phase I/II data

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 11/10/2014
  • LentiGlobin BB305 gene therapy: Phase I/II data

    bluebird bio Inc. (NASDAQ:BLUE), Cambridge, Mass. Product: LentiGlobin BB305 gene therapy Business: Hematology Molecular target: NA Description: Autologous CD34+ stem cells transduced ex vivo with a lentiviral vector …

    Published on 11/10/2014
  • Letairis: Phase IIIb/IV data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Letairis ( Volibris-EU) ambrisentan Business: Cardiovascular Molecular target: Endothelin A receptor…

    Published on 11/10/2014
  • ND0612H: Preliminary Phase IIa data

    NeuroDerm Ltd., Ness Ziona, Israel Product: ND0612H Business: Neurology Molecular target: NA Description: High-dose formulation of liquid levodopa and carbidopa delivered via a continuous, subcutaneous belt pump …

    Published on 11/10/2014
  • ND0612L: Phase II data

    NeuroDerm Ltd., Ness Ziona, Israel Product: ND0612L Business: Neurology Molecular target: NA Description: Low-dose formulation of liquid levodopa and carbidopa delivered via a continuous, subcutaneous belt pump …

    Published on 11/10/2014
  • Raplixa: Additional Phase III data

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. Product: Raplixa (formerly Fibrocaps) Business: Hematology Molecular target: NA Description: Dry powder topical fibrin sealant composed of fibrinogen and thrombin …

    Published on 11/10/2014
  • REC 0482: Phase III data

    Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec Recordati S.p.A. (Milan:REC), Milan, Italy Product: REC 0482, NX-1207 Business: Genitourinary Molecular target: Undisclosed Description: Undisclosed …

    Published on 11/10/2014
  • REC 0482: Phase III data

    Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec Recordati S.p.A. (Milan:REC), Milan, Italy Product: REC 0482, NX-1207 Business: Genitourinary Molecular target: Undisclosed Description: Undisclosed …

    Published on 11/10/2014
  • Saxenda Liraglutide 3 mg: Additional Phase IIIa data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Saxenda Liraglutide 3 mg (NN8022) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 (GLP-1) Description: Human glucagon-like …

    Published on 11/10/2014
  • Subcutaneous immunoglobulin 20%: Phase II/III data

    Baxter International Inc. (NYSE:BAX), Deerfield, Ill. Product: Subcutaneous immunoglobulin 20% Business: Hematology Molecular target: NA Description: Subcutaneous immunoglobulin 20% Indication: Treat primary …

    Published on 11/10/2014
  • Tasquinimod: Preliminary Phase II data

    Active Biotech AB (SSE:ACTI), Lund, Sweden Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Tasquinimod (TASQ) (ABR-215050) Business: Cancer Molecular target: S100 calcium binding protein A9…

    Published on 11/10/2014
  • Trebananib: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Trebananib (AMG 386) Business: Cancer Molecular target: Angiopoietin 1 (ANG1) (ANGPT1); Angiopoietin 2 (…

    Published on 11/10/2014
  • Tresiba insulin degludec: Phase III data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Tresiba insulin degludec (NN1250) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Long-acting insulin analog …

    Published on 11/10/2014
  • AKB-6548: Phase IIb data

    Akebia Therapeutics Inc. (NASDAQ:AKBA), Cambridge, Mass. Product: AKB-6548 Business: Hematology Molecular target: Hypoxia-inducible factor prolyl hydroxylase (HIF-PH) (EGLN) Description: Oral hypoxia-inducible factor …

    Published on 11/3/2014
  • BACE1 inhibitor: Phase I data

    Vitae Pharmaceuticals Inc. (NASDAQ:VTAE), Fort Washington, Pa. Boehringer Ingelheim GmbH, Ingelheim, Germany Product: BACE1 inhibitor (VTP-37948, BI1181181) Business: Neurology Molecular target: Beta-site APP-cleaving …

    Published on 11/3/2014
  • BIND-014: Additional Phase II data

    Bind Therapeutics Inc. (NASDAQ:BIND), Cambridge, Mass. Product: BIND-014 Business: Cancer Molecular target: Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) Description: Polymeric nanoparticle containing …

    Published on 11/3/2014
  • CNV1014802: Phase II data

    Convergence Pharmaceuticals Ltd., Cambridge, U.K. Product: CNV1014802 Business: Neurology Molecular target: Nav1.7 (SCN9A) Description: State-dependent inhibitor of sodium channel subunit Nav1.7 (SCN9A) Indication: …

    Published on 11/3/2014
  • Cobimetinib: Additional Phase III data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Cobimetinib (RG7421, GDC-0973) (formerly XL518) Business: …

    Published on 11/3/2014
  • Everolimus: Phase III final data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Everolimus (Afinitor, Certican, Zortress, Votubia) (RAD001) Business: Cancer Molecular target: Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) …

    Published on 11/3/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993